339 related articles for article (PubMed ID: 35781456)
1. [Tolvaptan, a vasopressin V
Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
[TBL] [Abstract][Full Text] [Related]
2. An update on tolvaptan for autosomal dominant polycystic kidney disease.
Poch E; Rodas L; Blasco M; Molina A; Quintana L
Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
[TBL] [Abstract][Full Text] [Related]
3. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
4. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
Zhou JX; Torres VE
Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
[TBL] [Abstract][Full Text] [Related]
5. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
Olalekan K; Fox A; Gilbert R
Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
[TBL] [Abstract][Full Text] [Related]
6. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.
Reif GA; Yamaguchi T; Nivens E; Fujiki H; Pinto CS; Wallace DP
Am J Physiol Renal Physiol; 2011 Nov; 301(5):F1005-13. PubMed ID: 21816754
[TBL] [Abstract][Full Text] [Related]
9. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS
J Am Soc Nephrol; 2017 May; 28(5):1592-1602. PubMed ID: 27920153
[TBL] [Abstract][Full Text] [Related]
10. Review of tolvaptan for autosomal dominant polycystic kidney disease.
Baur BP; Meaney CJ
Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
12. Long-Residence Time Peptide Antagonist for the Vasopressin V
Xiong X; Wang N; Zhang Y; Zhao W; Pang N; Fu K; Zhou N; Zhou X; Guo D
J Med Chem; 2024 Apr; 67(7):5935-5944. PubMed ID: 38509003
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA; Keating GM
Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA
Drugs; 2019 Feb; 79(3):303-313. PubMed ID: 30689194
[TBL] [Abstract][Full Text] [Related]
15. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
16. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
17. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
Torres VE
Nephrol Dial Transplant; 2019 Jan; 34(1):30-34. PubMed ID: 30312438
[TBL] [Abstract][Full Text] [Related]
18. A
Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
[TBL] [Abstract][Full Text] [Related]
19. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
[TBL] [Abstract][Full Text] [Related]
20. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
Müller RU; Messchendorp AL; Birn H; Capasso G; Cornec-Le Gall E; Devuyst O; van Eerde A; Guirchoun P; Harris T; Hoorn EJ; Knoers NVAM; Korst U; Mekahli D; Le Meur Y; Nijenhuis T; Ong ACM; Sayer JA; Schaefer F; Servais A; Tesar V; Torra R; Walsh SB; Gansevoort RT
Nephrol Dial Transplant; 2022 Apr; 37(5):825-839. PubMed ID: 35134221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
